Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chlortalidone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Chlortalidone. Displaying page 1 of 1.
    EudraCT Number: 2014-000605-12 Sponsor Protocol Number: notapplicable1 Start Date*: 2014-06-13
    Sponsor Name:
    Full Title: Thiazide diuretics versus calcium channel blockers for the treatment of calcineurin inhibitor-induced hypertension in patients with psoriasis or eczema: a single-center randomized cross-over trial.
    Medical condition: Hypertension, induced by the use of a Calcineurin Inhibitor (CNI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004218-28 Sponsor Protocol Number: TAK-491CLD_302 Start Date*: 2009-11-26
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Subjects with Moderate to Severe Hypertension
    Medical condition: TAK-491CLD is being evaluated to treat moderate to severe essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008260-28 Sponsor Protocol Number: TAK-491CLD_308 Start Date*: 2010-02-03
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-D...
    Medical condition: TAK-491CLD is being evaluated to treat essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023098-21 Sponsor Protocol Number: TAK-491CLD_309 Start Date*: 2011-03-09
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fix...
    Medical condition: Hypertensive Subjects With Moderate Renal Impairment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10062237 Renal impairment LLT
    12.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) NL (Completed) SK (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-000220-16 Sponsor Protocol Number: TAK-491CLD_307 Start Date*: 2011-07-14
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essentia...
    Medical condition: Essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) NL (Completed) DE (Completed) SK (Completed) SE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000165-23 Sponsor Protocol Number: INFORM Start Date*: 2016-10-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM)
    Medical condition: Cardiovascular Hemodynamics
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10005727 Blood pressure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003873-13 Sponsor Protocol Number: ESR-14-10613/D1690L00044 Start Date*: 2016-02-25
    Sponsor Name:Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders
    Full Title: Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy.
    Medical condition: Diabetes mellitus type 2.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000966-10 Sponsor Protocol Number: 38/2004/U/sper Start Date*: 2004-03-23
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: na
    Medical condition: ESSENTIAL HYPERTENSION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10047065 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000414-20 Sponsor Protocol Number: CHANCE-HF Start Date*: 2011-08-02
    Sponsor Name:Consorcio de Apoyo a la Investigacion Biomedica en Red (CAIBER)
    Full Title: Ensayo aleatorizado controlado sobre la terapia guiada por el antígeno carbohidrato 125 en los pacientes dados de alta por insuficiencia cardiaca aguda: efecto sobre la mortalidad a 1 año.
    Medical condition: acute heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007556 Cardiac failure acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001809-16 Sponsor Protocol Number: Unidone-01 Start Date*: 2016-09-14
    Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    Full Title: Efficacy and safety of chlorthalidone 25 mg in hypertensive patients.
    Medical condition: BP lowering effect of chlorthalidone 25 mg in essential hypertensive patients.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10045866 Unspecified essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005426-18 Sponsor Protocol Number: DECONGEST_v1.0 Start Date*: 2022-03-02
    Sponsor Name:UZ Brussel
    Full Title: Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment
    Medical condition: Acute Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Dec 11 19:45:56 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA